AAPL345.97+2.06 (+0.60%) ▲|ABBV286.81+0.07 (+0.02%) ▲|ABT104.13-0.76 (-0.72%) ▼|ACN236.65-10.58 (-4.28%) ▼|ADBE249.57-9.05 (-3.50%) ▼|AMAT395.82+8.23 (+2.12%) ▲|AMD559.85+28.57 (+5.38%) ▲|AMGN446.95+2.32 (+0.52%) ▲|AMT183.14-5.15 (-2.73%) ▼|AMZN254.04+4.95 (+1.99%) ▲|AVGO341.92+12.75 (+3.87%) ▲|AXP313.40-1.66 (-0.53%) ▼|BA170.20-18.11 (-9.62%) ▼|BAC50.71+0.19 (+0.37%) ▲|BKNG150.71-2.44 (-1.59%) ▼|BLK1,131.37+3.71 (+0.33%) ▲|BMY61.29-0.32 (-0.52%) ▼|BNY147.72+0.54 (+0.37%) ▲|BRK-B545.02-3.54 (-0.65%) ▼|C122.68+1.64 (+1.35%) ▲|CAT713.23+21.10 (+3.05%) ▲|CL92.06-1.05 (-1.12%) ▼|CMCSA21.81-0.25 (-1.11%) ▼|COF204.16+1.81 (+0.89%) ▲|COP148.20-3.18 (-2.10%) ▼|COST992.04-13.12 (-1.31%) ▼|CRM241.95-5.66 (-2.29%) ▼|CSCO111.53+1.29 (+1.17%) ▲|CVS91.35-1.18 (-1.28%) ▼|CVX229.08-2.93 (-1.26%) ▼|DE639.64-1.61 (-0.25%) ▼|DHR232.12-0.85 (-0.36%) ▼|DIS109.86-0.54 (-0.49%) ▼|DUK124.10-0.34 (-0.27%) ▼|EMR165.60+3.90 (+2.41%) ▲|FDX307.15+6.57 (+2.19%) ▲|GD355.10-1.94 (-0.54%) ▼|GE298.08+9.65 (+3.35%) ▲|GEV887.49+32.87 (+3.85%) ▲|GILD157.94-0.75 (-0.47%) ▼|GM80.55+4.24 (+5.56%) ▲|GOOG318.30+4.11 (+1.31%) ▲|GOOGL321.90+5.10 (+1.61%) ▲|GS911.91+18.63 (+2.09%) ▲|HD318.79-0.59 (-0.18%) ▼|HON217.61-1.67 (-0.76%) ▼|IBM250.38-3.07 (-1.21%) ▼|INTC93.38+2.91 (+3.21%) ▲|INTU326.19-13.70 (-4.03%) ▼|ISRG446.61-5.02 (-1.11%) ▼|JNJ268.49+2.19 (+0.82%) ▲|JPM336.16+2.12 (+0.63%) ▲|KO91.65-1.05 (-1.13%) ▼|LIN507.11-0.45 (-0.09%) ▼|LLY1,281.29+2.15 (+0.17%) ▲|LMT623.94-11.26 (-1.77%) ▼|LOW197.99-0.23 (-0.12%) ▼|LRCX240.52+3.02 (+1.27%) ▲|MA607.95-5.55 (-0.90%) ▼|MCD249.67-1.17 (-0.46%) ▼|MDLZ62.05-0.93 (-1.47%) ▼|MDT94.36-0.43 (-0.45%) ▼|META622.57-8.00 (-1.27%) ▼|MMM171.83-0.96 (-0.56%) ▼|MO73.35-0.28 (-0.37%) ▼|MRK142.18+1.57 (+1.12%) ▲|MS187.39+3.90 (+2.13%) ▲|MSFT531.20-1.40 (-0.26%) ▼|MU931.47+27.77 (+3.07%) ▲|NEE82.19+0.15 (+0.18%) ▲|NFLX62.71-1.20 (-1.87%) ▼|NKE37.44-0.48 (-1.25%) ▼|NOW155.64-2.54 (-1.61%) ▼|NVDA217.78+1.78 (+0.82%) ▲|ORCL131.60+5.54 (+4.39%) ▲|PEP132.66-2.80 (-2.07%) ▼|PFE29.75-0.05 (-0.15%) ▼|PG158.98-0.94 (-0.59%) ▼|PLTR199.44+0.60 (+0.30%) ▲|PM203.18+1.31 (+0.65%) ▲|QCOM181.79+2.19 (+1.22%) ▲|RTX195.29-2.20 (-1.11%) ▼|SBUX102.52-0.18 (-0.17%) ▼|SCHW89.62-0.11 (-0.12%) ▼|SO92.14-0.44 (-0.47%) ▼|SPG211.92-0.77 (-0.36%) ▼|T20.98+0.13 (+0.60%) ▲|TMO698.34+13.45 (+1.96%) ▲|TMUS147.04+0.11 (+0.07%) ▲|TSLA406.03+14.41 (+3.68%) ▲|TXN307.36+9.24 (+3.10%) ▲|UBER65.90-0.24 (-0.36%) ▼|UNH409.45-1.25 (-0.30%) ▼|UNP299.26+2.29 (+0.77%) ▲|UPS105.72+5.40 (+5.38%) ▲|USB59.77+0.07 (+0.11%) ▲|V398.62-5.54 (-1.37%) ▼|VZ43.79+0.69 (+1.59%) ▲|WFC82.76+0.11 (+0.13%) ▲|WMT118.96-1.34 (-1.11%) ▼|XOM180.97-3.57 (-1.93%) ▼|AAPL345.97+2.06 (+0.60%) ▲|ABBV286.81+0.07 (+0.02%) ▲|ABT104.13-0.76 (-0.72%) ▼|ACN236.65-10.58 (-4.28%) ▼|ADBE249.57-9.05 (-3.50%) ▼|AMAT395.82+8.23 (+2.12%) ▲|AMD559.85+28.57 (+5.38%) ▲|AMGN446.95+2.32 (+0.52%) ▲|AMT183.14-5.15 (-2.73%) ▼|AMZN254.04+4.95 (+1.99%) ▲|AVGO341.92+12.75 (+3.87%) ▲|AXP313.40-1.66 (-0.53%) ▼|BA170.20-18.11 (-9.62%) ▼|BAC50.71+0.19 (+0.37%) ▲|BKNG150.71-2.44 (-1.59%) ▼|BLK1,131.37+3.71 (+0.33%) ▲|BMY61.29-0.32 (-0.52%) ▼|BNY147.72+0.54 (+0.37%) ▲|BRK-B545.02-3.54 (-0.65%) ▼|C122.68+1.64 (+1.35%) ▲|CAT713.23+21.10 (+3.05%) ▲|CL92.06-1.05 (-1.12%) ▼|CMCSA21.81-0.25 (-1.11%) ▼|COF204.16+1.81 (+0.89%) ▲|COP148.20-3.18 (-2.10%) ▼|COST992.04-13.12 (-1.31%) ▼|CRM241.95-5.66 (-2.29%) ▼|CSCO111.53+1.29 (+1.17%) ▲|CVS91.35-1.18 (-1.28%) ▼|CVX229.08-2.93 (-1.26%) ▼|DE639.64-1.61 (-0.25%) ▼|DHR232.12-0.85 (-0.36%) ▼|DIS109.86-0.54 (-0.49%) ▼|DUK124.10-0.34 (-0.27%) ▼|EMR165.60+3.90 (+2.41%) ▲|FDX307.15+6.57 (+2.19%) ▲|GD355.10-1.94 (-0.54%) ▼|GE298.08+9.65 (+3.35%) ▲|GEV887.49+32.87 (+3.85%) ▲|GILD157.94-0.75 (-0.47%) ▼|GM80.55+4.24 (+5.56%) ▲|GOOG318.30+4.11 (+1.31%) ▲|GOOGL321.90+5.10 (+1.61%) ▲|GS911.91+18.63 (+2.09%) ▲|HD318.79-0.59 (-0.18%) ▼|HON217.61-1.67 (-0.76%) ▼|IBM250.38-3.07 (-1.21%) ▼|INTC93.38+2.91 (+3.21%) ▲|INTU326.19-13.70 (-4.03%) ▼|ISRG446.61-5.02 (-1.11%) ▼|JNJ268.49+2.19 (+0.82%) ▲|JPM336.16+2.12 (+0.63%) ▲|KO91.65-1.05 (-1.13%) ▼|LIN507.11-0.45 (-0.09%) ▼|LLY1,281.29+2.15 (+0.17%) ▲|LMT623.94-11.26 (-1.77%) ▼|LOW197.99-0.23 (-0.12%) ▼|LRCX240.52+3.02 (+1.27%) ▲|MA607.95-5.55 (-0.90%) ▼|MCD249.67-1.17 (-0.46%) ▼|MDLZ62.05-0.93 (-1.47%) ▼|MDT94.36-0.43 (-0.45%) ▼|META622.57-8.00 (-1.27%) ▼|MMM171.83-0.96 (-0.56%) ▼|MO73.35-0.28 (-0.37%) ▼|MRK142.18+1.57 (+1.12%) ▲|MS187.39+3.90 (+2.13%) ▲|MSFT531.20-1.40 (-0.26%) ▼|MU931.47+27.77 (+3.07%) ▲|NEE82.19+0.15 (+0.18%) ▲|NFLX62.71-1.20 (-1.87%) ▼|NKE37.44-0.48 (-1.25%) ▼|NOW155.64-2.54 (-1.61%) ▼|NVDA217.78+1.78 (+0.82%) ▲|ORCL131.60+5.54 (+4.39%) ▲|PEP132.66-2.80 (-2.07%) ▼|PFE29.75-0.05 (-0.15%) ▼|PG158.98-0.94 (-0.59%) ▼|PLTR199.44+0.60 (+0.30%) ▲|PM203.18+1.31 (+0.65%) ▲|QCOM181.79+2.19 (+1.22%) ▲|RTX195.29-2.20 (-1.11%) ▼|SBUX102.52-0.18 (-0.17%) ▼|SCHW89.62-0.11 (-0.12%) ▼|SO92.14-0.44 (-0.47%) ▼|SPG211.92-0.77 (-0.36%) ▼|T20.98+0.13 (+0.60%) ▲|TMO698.34+13.45 (+1.96%) ▲|TMUS147.04+0.11 (+0.07%) ▲|TSLA406.03+14.41 (+3.68%) ▲|TXN307.36+9.24 (+3.10%) ▲|UBER65.90-0.24 (-0.36%) ▼|UNH409.45-1.25 (-0.30%) ▼|UNP299.26+2.29 (+0.77%) ▲|UPS105.72+5.40 (+5.38%) ▲|USB59.77+0.07 (+0.11%) ▲|V398.62-5.54 (-1.37%) ▼|VZ43.79+0.69 (+1.59%) ▲|WFC82.76+0.11 (+0.13%) ▲|WMT118.96-1.34 (-1.11%) ▼|XOM180.97-3.57 (-1.93%) ▼|
16.8 C
New York
Tuesday, October 27, 2026

Tag: trials

newsFORsourcecompanycontentinformation1releasesmarket

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development,...

2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research,...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than TripledLate-Breaking Phase 3 DeLLphi-305 Results Presented in...

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk...

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgeryTwice as...

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced the presentation...

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across...

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment BiologySEOUL, South Korea, Oct. 24,...

Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026

~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and...

Driving hope in Quebec: Hyundai Hope on Wheels wraps 2026 with significant donations in Quebec City and Montréal

Last leg of the 2026 Hyundai Hope on Wheels tour wraps up with $433,500 in donations to Fondation Charles-Bruneau in Quebec City and the CHU...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of...

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie’s SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn’s Disease

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the...

UCB Establishes the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women’s Hospital

Permanent endowment advances pharmacoepidemiology and real-world evidence researchSebastian Schneeweiss, MD, ScD, an internationally recognized pharmacoepidemiologist whose research focuses on improving medication safety, effectiveness, and...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrials

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers